ATH alterity therapeutics limited

hsg summary of accomplishments, page-7

  1. 158 Posts.
    Those two recent Oct 29 presentations are the 2013 updates and do not mention REACH2HD, and the silence is deafening in a good way. Her audience you will find include trial participants I believe and it is as if they were coached in advance there will be no mention of REACH2HD. Perhaps on sign at the front entrance or somewhere on the chalk board w/smileys....

    It is actually those two presentations (which I have mostly forgotten) that contain the best explanations I have ever come across distinguishing the differences in the parts of the brain affected by AD, HD, and Parkinsons, and also the differences in symptoms, where I think with HD the information/memories are still there by its a mechanism of retrieval problem.

    Also a pretty cool advance this past year in tests that hone in on early detections of disease.

    If you have ever experience Brochea's aphasia (spelling?) where you can't spit the word out (which I have at times been there thanks to a head injury).

    From a REACH2HD testimonial the 2012 is the one. From the educational aspect of understanding the diseases and what parts of the brain are impacted by them - these recent two are absolutely wonderful - must watch videos...

    http://vimeo.com/78077486

    Part II is the Q & A, but I liked it....
    http://vimeo.com/78074591
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.3¢
Change
0.002(18.2%)
Mkt cap ! $118.6M
Open High Low Value Volume
1.2¢ 1.3¢ 1.2¢ $174.2K 14.29M

Buyers (Bids)

No. Vol. Price($)
8 2754250 1.2¢
 

Sellers (Offers)

Price($) Vol. No.
1.3¢ 3646759 13
View Market Depth
Last trade - 16.10pm 17/07/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.